Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mayne Pharma Group ( (AU:MYX) ) has shared an announcement.
Mayne Pharma Group has announced that director Shawn Patrick O’Brien has ceased to be a director of the company as of 20 February 2026 (U.S. time). The final director’s interest notice lodged with the ASX details O’Brien’s remaining holdings in Mayne Pharma, including performance rights and ordinary shares held directly and through a custodian under the company’s performance rights and option plan, providing transparency for investors on his equity position at the time of departure.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australia-listed specialty pharmaceutical company. It develops, manufactures and markets branded and generic medicines, with a focus on regulated markets such as the U.S. and Australia, serving healthcare providers and patients through a portfolio of oral and other dosage-form products.
YTD Price Performance: -14.79%
Average Trading Volume: 503,275
Technical Sentiment Signal: Sell
Current Market Cap: A$214.5M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.